0000014272-17-000130.txt : 20170427 0000014272-17-000130.hdr.sgml : 20170427 20170427082634 ACCESSION NUMBER: 0000014272-17-000130 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20170427 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170427 DATE AS OF CHANGE: 20170427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 17786356 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 q12017earningsrelease8-k.htm 8-K Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported): April 27, 2017
 
 
BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)
 
 
 
 
 
 
 
 
Delaware
 
1-1136
 
22-0790350
(State or Other
Jurisdiction of
Incorporation)
 
(Commission File
Number)
 
(IRS Employer
Identification
Number)
345 Park Avenue
New York, NY 10154
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (212) 546-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 









Item 2.02. Results of Operations and Financial Condition.

On April 27, 2017, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the first quarter of 2017. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.
 
 
99.1
Press release of Bristol-Myers Squibb Company dated April 27, 2017.
 
 
99.2
Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.











































SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 



 
 
BRISTOL-MYERS SQUIBB COMPANY
 
 
 
 
 
Dated: April 27, 2017
 
By:
 
/s/ Katherine R. Kelly
 
 
 
Name:
 
Katherine R. Kelly
 
 
 
Title:
 
Corporate Secretary
 

                           















































EXHIBIT INDEX
 
 
 
Exhibit No.
Description
 
 
99.1
Press release of Bristol-Myers Squibb Company dated April 27, 2017.
 
 
99.2
Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.





 EX-99.1 2 q12017ex991.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED APRIL 27, 2017 Exhibit


Exhibit 99.1
bmslogoq12017.jpg

Bristol-Myers Squibb Reports First Quarter Financial Results

•
Increases First Quarter Revenues 12% to $4.9 Billion
•
Posts First Quarter GAAP EPS of $0.94 and Non-GAAP EPS of $0.84
•
Achieves Key Regulatory Milestones For Opdivo in the U.S. and Europe
•
Advances Immuno-Oncology Collaborations with Incyte and Exelixis to include Phase 3 Trials
•
Increases 2017 GAAP and Non-GAAP EPS Guidance

(NEW YORK, April 27, 2017) - Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2017, which were highlighted by strong sales for key products Opdivo and Eliquis, regulatory approval for Opdivo in advanced bladder cancer in the U.S., positive opinions from the Committee for Medicinal Products for Human Use (CHMP) for advanced bladder and head and neck cancers in Europe, and strategic transactions in oncology that further strengthened the company’s pipeline.

“During the first quarter we delivered strong sales and earnings growth, achieved important regulatory milestones for Opdivo in the U.S. and Europe and presented important new data across our Immuno-Oncology and fibrosis portfolios,” said Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb. “Building on this strong start to the year, we will continue to drive commercial performance in the short-term while advancing important opportunities to broaden our approach in Immuno-Oncology and progressing our early specialty portfolio.”

 
First Quarter
$ amounts in millions, except per share amounts
 
 
 
 
 
 
2017
 
2016
 
Change
Total Revenues
$
4,929

 
$
4,391

 
12
%
GAAP Diluted EPS
0.94

 
0.71

 
32
%
Non-GAAP Diluted EPS
$
0.84

 
$
0.74

 
14
%











1



FIRST QUARTER FINANCIAL RESULTS

•
Bristol-Myers Squibb posted first quarter 2017 revenues of $4.9 billion, an increase of 12% compared to the same period a year ago. Revenues increased 13% when adjusted for foreign exchange impact.

•
U.S. revenues increased 8% to $2.7 billion in the quarter compared to the same period a year ago. International revenues increased 18%. When adjusted for foreign exchange impact, international revenues increased 20%.

•
Gross margin as a percentage of revenue decreased from 76.0% to 74.5% in the quarter primarily due to product mix.

•
Marketing, selling and administrative expenses increased 1% to $1.1 billion in the quarter.

•
Research and development expenses increased 13% to $1.3 billion in the quarter.

•
The effective tax rate was 21.9% in the quarter, compared to 27.1% in the first quarter last year.

•
The company reported net earnings attributable to Bristol-Myers Squibb of $1.6 billion, or $0.94 per share, in the first quarter compared to net earnings of $1.2 billion, or $0.71 per share, for the same period in 2016. The results for the first quarter of 2017 included Bristol-Myers Squibb’s share of a patent-infringement litigation settlement related to Merck’s PD-1 antibody Keytruda® that contributed $0.18 per share.

•
The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $1.4 billion, or $0.84 per share, in the first quarter, compared to $1.2 billion, or $0.74 per share, for the same period in 2016. An overview of specified items is discussed under the “Use of Non-GAAP Financial Information” section.

•
Cash, cash equivalents and marketable securities were $8.8 billion, with a net cash position of $360 million, as of March 31, 2017.







2



FIRST QUARTER PRODUCT AND PIPELINE UPDATE
Product Sales/Business Highlights
The increase in global revenues for the first quarter of 2017, compared to the first quarter of 2016, was driven by:
Product
Growth %
Opdivo
60%
Eliquis
50%
Yervoy
25%
Sprycel
14%
Orencia
13%

Opdivo

Regulatory

•
In April, the company announced the CHMP recommended the approval of Opdivo for the treatment of patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing chemotherapy. The CHMP recommendation will be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU).

•
In April, the company announced the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application seeking to extend the use of Opdivo to patients with mismatch repair deficient or microsatellite instability high metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. The FDA granted the application priority review and the FDA action date is August 2, 2017.

•
In April, the FDA approved an updated indication for Opdivo for the treatment of adult patients with Classical Hodgkin lymphoma that have relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or three or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

•
In March, the company announced the CHMP recommended the approval of Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy. The CHMP recommendation will be reviewed by the EC.

3



•
In March, the company and its partner Ono Pharmaceutical Co. announced the approval of Opdivo as monotherapy for the treatment of recurrent or metastatic head and neck cancer in Japan.

•
In February, the company announced the FDA provided accelerated approval for Opdivo for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Clinical
•
In April, at the American Association for Cancer Research (AACR) Annual Meeting, the company announced new data and analysis from studies evaluating Opdivo and the Opdivo + Yervoy regimen:
◦
First overall survival results from CheckMate -067, a Phase 3 trial of Opdivo and the Opdivo + Yervoy regimen versus Yervoy alone in patients with previously untreated advanced melanoma. More detail of the study results is included in the original press release (link).
◦
The first report of five-year overall survival data from the Phase 1 dose-ranging study CA209-003 evaluating Opdivo in patients with previously treated advanced non-small cell lung cancer. More detail of the study results is included in the original press release (link).

•
In April, the company announced CheckMate -143, a randomized Phase 3 clinical trial evaluating the efficacy and safety of Opdivo in patients with first recurrence of glioblastoma multiforme did not meet its primary endpoint of improved overall survival over bevacizumab monotherapy.

Sprycel
•
In February, the company announced the European Patent Office (EPO) upheld a decision finding European Patent No. 1169038 (the '038 patent), the Composition of Matter patent covering dasatinib, the active ingredient in Sprycel, to be invalid. The decision does not impact patents outside of the EU or other Sprycel-related patents. Additionally in February, the EPO Board of Appeal reversed and remanded an invalidity decision on European Patent No. 1610780 and its claim to the use of dasatinib to treat chronic myeloid leukemia (CML), which the EPO's Opposition Division had revoked in October 2012. The company intends to take appropriate legal actions to protect Sprycel.

4




Eliquis
•
In March, at the American College of Cardiology’s (ACC) Annual Scientific Session, the company and its partner Pfizer Inc. announced findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants Eliquis, dabigatran or rivaroxaban versus warfarin. More detail of the analysis is included in the original press release (link).

Fibrosis
•
In April, at EASL: The International Liver Congress, the company announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21), a key regulator of metabolism, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH ) (F1-F3). The study achieved its primary endpoint of significant reduction in liver fat versus placebo, and also showed improvement in markers of liver injury and fibrosis.

FIRST QUARTER BUSINESS DEVELOPMENT UPDATE

•
In April, the company and Transgene announced a clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Opdivo + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1.

•
In April, the company and Apexigen, Inc. announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Apexigen’s APX005M with Opdivo in patients with second-line metastatic NSCLC who have failed prior chemotherapy, and in metastatic melanoma patients who have failed prior Immuno-Oncology (I-O) therapy.

•
In April, the company and Nordic Bioscience announced a collaboration to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including NASH.

5




•
In April, the company announced it entered into two separate agreements to outlicense BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy, to Biogen, and BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy, to Roche. The company will receive upfront payments of $300 million from Biogen and $170 million from Roche, along with potential milestone payments and royalties from each company.

•
In April, the company and Incyte Corporation announced an agreement to advance their clinical development program evaluating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Opdivo into Phase 3 registrational studies in first-line NSCLC across the spectrum of PD-L1 expression and first-line head and neck cancer. Additionally, the companies are expanding the ECHO-204 Phase 1/2 study, established under a collaboration between the companies in 2014, to include anti-PD-1/PD-L1 relapsed/refractory melanoma cohorts.

•
In March, the company and Foundation Medicine announced a collaboration to leverage Foundation Medicine’s comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tumor Mutational Burden and Microsatellite Instability in patients enrolled across clinical trials investigating Bristol-Myers Squibb’s cancer immunotherapies.

•
In March, the company, the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) announced a multi-year collaboration agreement to coordinate and rapidly initiate clinical I-O studies across the Parker Institute and CRI networks.

•
In March, the company and CytomX Therapeutics, Inc. announced an expansion of their collaboration to discover novel therapies against multiple I-O targets using CytomX’s proprietary Probody® Platform, expanding the number of targets from four to twelve.

•
In March, the company announced an equity investment and plans for a research collaboration with GRAIL Inc. that grants the company early access to GRAIL’s comprehensive clinical trial databases that may help improve understanding of tumor genomics. Additionally, Bristol-Myers Squibb will utilize GRAIL’s analytics tools to inform research, advance diagnostics and improve patient outcomes.





6



•
In February, the company and Exelixis, Inc. announced a clinical development collaboration to evaluate Cabometyx® (cabozantinib), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo, either alone or in combination with Yervoy. The agreement is expected to include a Phase 3 pivotal trial in first-line renal cell carcinoma, with additional trials planned in bladder cancer, hepatocellular carcinoma (HCC), and potentially other tumor types.

•
In February, the company announced an expansion of the five-year old International Immuno-Oncology Network (II-ON) with the addition of Columbia University Medical Center and Peter MacCallum Cancer Centre (Peter Mac). II-ON is a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to advance I-O science and translational medicine to improve patient outcomes.

SHARE REPURCHASE

In February, the company executed accelerated share repurchase (ASR) agreements to repurchase, in aggregate, $2 billion of the company’s common stock. The ASR was funded through a combination of debt and cash and is part of the company’s existing share repurchase authorization. Approximately 80 percent of the shares to be repurchased under the transaction were received by the company on February 28, 2017 and the company anticipates that all repurchases under the ASR will be completed by the end of the second quarter of 2017.

The decision reflects the company’s strong financial position and its balanced approach to capital allocation, including a commitment to its dividend and a disciplined approach to business development.

2017 FINANCIAL GUIDANCE

Bristol-Myers Squibb is increasing its 2017 GAAP EPS guidance range from $2.47- $2.67 to $2.72 - $2.87 and is increasing its non-GAAP EPS guidance range from $2.70 - $2.90 to $2.85 - $3.00. Both GAAP and non-GAAP guidance assume current exchange rates. Key revised 2017 GAAP and non-GAAP line-item guidance assumptions are:

•
Worldwide revenues increasing in the mid-single digits.
•
Research and development expenses increasing in the high-teens digit range for GAAP and increasing in the low-double digits range for non-GAAP.
•
An effective tax rate of approximately 22% for GAAP with non-GAAP remaining at approximately 21%.

7




The financial guidance excludes the impact of any potential future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. The non-GAAP guidance also excludes other specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling GAAP amounts to non-GAAP amounts, with non-GAAP reflecting specified items are provided in supplemental materials attached to this press release and available on the company’s website.

Keytruda® is a trademark of Merck & Co., Inc.
Probody® Platform is a trademark of CytomX Therapeutics, Inc.
Cabometyx® is a trademark of Exelixis, Inc.

Use of Non-GAAP Financial Information

This press release contains non-GAAP financial measures, including non-GAAP earnings and related EPS information, that are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods including restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges in connection with the acquisition or licensing of third party intellectual property rights, divestiture gains or losses, upfront payments from out licensed assets, pension charges, legal and other contractual settlements and debt redemption gains or losses, among other items. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Non-GAAP information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. For example, non-GAAP earnings and EPS information is an indication of our baseline performance before items that are considered by us to not be reflective of our ongoing results. In addition, this information is among the primary indicators we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid,

8



Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. These factors also include the company’s ability to execute successfully its strategic plans, including its business development strategy, the expiration of patents or data protection on certain products, including assumptions about the company’s ability to retain patent exclusivity of certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the compounds will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


Company and Conference Call Information
    
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

There will be a conference call on April 27, 2017 at 10:30 a.m. EDT during which company executives will review financial information and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by calling the U.S. toll free 855-303-0072 or international 913-312-0976, confirmation code: 500711. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:30 p.m. EDT on April 27, 2017 through 1:30 p.m. EDT on May 11, 2017. The replay will also be available through http://investor.bms.com or by calling the U.S. toll free 888-203-1112 or international 719-457-0820, confirmation code: 6160500.

For more information, contact: Lisa McCormick Lavery, 609-252-7602, lisa.mccormicklavery@bms.com, or Ken Dominski, 609-252-5251, ken.dominski@bms.com, Communications; John Elicker, 609-252-4611, john.elicker@bms.com, Tim Power, 609-252-7509, timothy.power@bms.com or Bill Szablewski, 609-252-5894, william.szablewski@bms.com, Investor Relations.

9



BRISTOL-MYERS SQUIBB COMPANY
PRODUCT REVENUE
FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND 2016
(Unaudited, dollars in millions)
 
 
Worldwide Revenues
 
U.S. Revenues
 
 
2017
 
2016
 
%
Change
 
2017
 
2016
 
%
Change
Three Months Ended March 31,
 
 
 
 
 
 
 
 
 
 
 
 
Prioritized Brands
 
 
 
 
 
 
 
 
 
 
 
 
Opdivo
 
$
1,127

 
$
704

 
60
 %
 
$
761

 
$
594

 
28
 %
Eliquis
 
1,101

 
734

 
50
 %
 
699

 
468

 
49
 %
Orencia
 
535

 
475

 
13
 %
 
362

 
321

 
13
 %
Sprycel
 
463

 
407

 
14
 %
 
247

 
210

 
18
 %
Yervoy
 
330

 
263

 
25
 %
 
243

 
199

 
22
 %
Empliciti
 
53

 
28

 
89
 %
 
36

 
28

 
29
 %
Established Brands
 
 
 
 
 
 
 
 
 
 
 
 
Hepatitis C Franchise
 
162

 
427

 
(62
)%
 
42

 
259

 
(84
)%
Baraclude
 
282

 
291

 
(3
)%
 
14

 
17

 
(18
)%
Sustiva Franchise
 
184

 
273

 
(33
)%
 
153

 
228

 
(33
)%
Reyataz Franchise
 
193

 
221

 
(13
)%
 
88

 
120

 
(27
)%
Other Brands
 
499

 
568

 
(12
)%
 
93

 
93

 
—

 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
$
4,929

 
$
4,391

 
12
 %
 
$
2,738

 
$
2,537

 
8
 %
 
 
 


10



BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND 2016
(Unaudited, dollars and shares in millions except per share data)
 
 
 
Three Months Ended
March 31,
 
 
2017
 
2016
Net product sales
 
$
4,580

 
$
3,964

Alliance and other revenues
 
349

 
427

Total Revenues
 
4,929

 
4,391

 
 
 
 
 
Cost of products sold
 
1,259

 
1,052

Marketing, selling and administrative
 
1,074

 
1,068

Research and development
 
1,288

 
1,136

Other (income)/expense
 
(647
)
 
(520
)
Total Expenses
 
2,974

 
2,736

 
 
 
 
 
Earnings Before Income Taxes
 
1,955

 
1,655

Provision for Income Taxes
 
429

 
449

 
 
 
 
 
Net Earnings
 
1,526

 
1,206

Net Earnings/(Loss) Attributable to Noncontrolling Interest
 
(48
)
 
11

Net Earnings Attributable to BMS
 
$
1,574

 
$
1,195

 
 
 
 
 
Average Common Shares Outstanding:
 
 
 
 
Basic
 
1,662

 
1,669

Diluted
 
1,671

 
1,680

 
 
 
 
 
Earnings per Common Share
 
 
 
 
Basic
 
$
0.95

 
$
0.72

Diluted
 
$
0.94

 
$
0.71

 
 
 
 
 
Other (Income)/Expense
 
 
 
 
Interest expense
 
$
45

 
$
43

Investment income
 
(33
)
 
(24
)
Provision for restructuring
 
164

 
4

Litigation and other settlements
 
(484
)
 
43

Equity in net income of affiliates
 
(18
)
 
(26
)
Divestiture gains
 
(127
)
 
(270
)
Royalties and licensing income
 
(199
)
 
(254
)
Transition and other service fees
 
(7
)
 
(53
)
       Pension charges
 
33

 
22

Intangible asset impairments
 
—

 
15

Other
 
(21
)
 
(20
)
Other (income)/expense
 
$
(647
)
 
$
(520
)



11



BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND 2016
(Unaudited, dollars in millions)
 
 
 
Three Months Ended
March 31,
 
 
2017
 
2016
Cost of products sold(a)
 
$
—

 
$
4

 
 
 
 
 
License and asset acquisition charges
 
50

 
125

IPRD impairments
 
75

 
—

Accelerated depreciation and other
 
72

 
13

Research and development
 
197

 
138

 
 
 
 
 
Provision for restructuring
 
164

 
4

Divestiture gains
 
(100
)
 
(269
)
Pension charges
 
33

 
22

Litigation and other settlements
 
(481
)
 
43

Intangible asset impairments
 
—

 
15

Other (income)/expense
 
(384
)
 
(185
)
 
 
 
 
 
Decrease to pretax income
 
(187
)
 
(43
)
 
 
 
 
 
Income taxes on specified items
 
72

 
83

 
 
 
 
 
Increase/(decrease) to net earnings
 
(115
)
 
40

 
 
 
 
 
Noncontrolling interest
 
(59
)
 
—

 
 
 
 
 
Increase/(decrease) to net earnings used for diluted Non-GAAP EPS calculation
 
$
(174
)
 
$
40


(a)
Specified items in cost of products sold are accelerated depreciation, asset impairment and other shutdown costs.


12



BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS
FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND 2016
(Unaudited, dollars in millions)

 
Three Months Ended March 31, 2017
 
GAAP
 
Specified
Items(a)
 
Non-
GAAP
Gross Profit
$
3,670

 
$
—

 
$
3,670

Research and development
1,288

 
(197
)
 
1,091

Other (income)/expense
(647
)
 
384

 
(263
)
Earnings Before Income Taxes
1,955

 
(187
)
 
1,768

Provision for Income Taxes
429

 
72

 
357

Noncontrolling interest
(48
)
 
(59
)
 
11

 
 
 
 
 
 
Net Earnings Attributable to BMS used for Diluted EPS Calculation
$
1,574

 
$
(174
)
 
$
1,400

 
 
 
 
 
 
Average Common Shares Outstanding - Diluted
1,671

 
1,671

 
1,671

Diluted Earnings Per Share
$
0.94

 
$
(0.10
)
 
$
0.84

 
 
 
 
 
 
Effective Tax Rate
21.9
%
 
(1.7
)%
 
20.2
%
 
 
 
 
 
 
 
Three Months Ended March 31, 2016
 
GAAP
 
Specified
Items(a)
 
Non-
GAAP
Gross Profit
$
3,339

 
$
4

 
$
3,343

Research and development
1,136

 
(138
)
 
998

Other (income)/expense
(520
)
 
185

 
(335
)
Earnings Before Income Taxes
1,655

 
(43
)
 
1,612

Provision for Income Taxes
449

 
83

 
366

Noncontrolling interest
11

 
—

 
11

 
 
 
 
 
 
Net Earnings Attributable to BMS used for Diluted EPS Calculation
$
1,195

 
$
40

 
$
1,235

 
 
 
 
 
 
Average Common Shares Outstanding - Diluted
1,680

 
1,680

 
1,680

Diluted Earnings Per Share
$
0.71

 
$
0.03

 
$
0.74

 
 
 
 
 
 
Effective Tax Rate
27.1
%
 
(4.4
)%
 
22.7
%
(a)
Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.


13



BRISTOL-MYERS SQUIBB COMPANY
NET CASH/(DEBT) CALCULATION
AS OF MARCH 31, 2017 AND DECEMBER 31, 2016
(Unaudited, dollars in millions)
 
 
 
March 31, 2017
 
December 31, 2016
Cash and cash equivalents
 
$
3,910

 
$
4,237

Marketable securities - current
 
2,199

 
2,113

Marketable securities - non-current
 
2,685

 
2,719

     Cash, cash equivalents and marketable securities
 
8,794

 
9,069

Short-term debt obligations
 
(1,197
)
 
(992
)
Long-term debt
 
(7,237
)
 
(5,716
)
     Net cash position
 
$
360

 
$
2,361



14

 EX-99.2 3 q12017ex992.htm CERTAIN SUPPLEMENTAL INFORMATION Exhibit

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY
QUARTERLY TREND ANALYSIS OF REVENUES
(Unaudited, dollars in millions)
Revenues
 
2016
 
2017
 
% Change
 
FX Impact
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
 
Qtr vs. Qtr
 
YTD vs. YTD
    United States
 
$
2,537

 
$
2,688

 
$
5,225

 
$
2,790

 
$
8,015

 
$
2,705

 
$
10,720

 
$
2,738

 

 

 

 

 

 

 
8%
 
8%
 
—
 
—
    Europe
 
870

 
1,039

 
1,909

 
946

 
2,855

 
1,360

 
4,215

 
1,146

 

 

 

 

 

 

 
32%
 
32%
 
(5)%
 
(5)%
    Rest of the World
 
840

 
1,013

 
1,853

 
1,069

 
2,922

 
1,042

 
3,964

 
925

 

 

 

 

 

 

 
10%
 
10%
 
1%
 
1%
    Other
 
144

 
131

 
275

 
117

 
392

 
136

 
528

 
120

 

 

 

 

 

 

 
(17)%
 
(17)%
 
N/A
 
N/A
Total
 
$
4,391

 
$
4,871

 
$
9,262

 
$
4,922

 
$
14,184

 
$
5,243

 
$
19,427

 
$
4,929

 

 

 

 

 

 

 
12%
 
12%
 
(1)%
 
(1)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% of Revenues
 
2016
 
2017
 
 
 
 
 
 
 
 
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
 
 
 
 
 
 
 
    United States
 
57.8
%
 
55.2
%
 
56.4
%
 
56.7
%
 
56.5
%
 
51.6
%
 
55.2
%
 
55.5
%
 

 

 

 

 

 

 
 
 
 
 
 
 
 
    Europe
 
19.8
%
 
21.3
%
 
20.6
%
 
19.2
%
 
20.1
%
 
25.9
%
 
21.7
%
 
23.3
%
 

 

 

 

 

 

 
 
 
 
 
 
 
 
    Rest of the World
 
19.1
%
 
20.8
%
 
20.0
%
 
21.7
%
 
20.6
%
 
19.9
%
 
20.4
%
 
18.8
%
 

 

 

 

 

 

 
 
 
 
 
 
 
 
    Other
 
3.3
%
 
2.7
%
 
3.0
%
 
2.4
%
 
2.8
%
 
2.6
%
 
2.7
%
 
2.4
%
 

 

 

 

 

 

 
 
 
 
 
 
 
 
Total
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
 

 

 

 

 

 

 
 
 
 
 
 
 
 


1

BRISTOL-MYERS SQUIBB COMPANY
EARNINGS FROM OPERATIONS
(Unaudited, dollars and shares in millions except per share data)
 
 
2016
 
2017
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Net product sales
 
$
3,964

 
$
4,432

 
$
8,396

 
$
4,492

 
$
12,888

 
$
4,814

 
$
17,702

 
$
4,580

 

 

 

 

 

 

 
16%
 
16%
Alliance and other revenues
 
427

 
439

 
866

 
430

 
1,296

 
429

 
1,725

 
349

 

 

 

 

 

 

 
(18)%
 
(18)%
Total Revenues
 
$
4,391

 
$
4,871

 
$
9,262

 
$
4,922

 
$
14,184

 
$
5,243

 
$
19,427

 
$
4,929

 

 

 

 

 

 

 
12%
 
12%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cost of products sold
 
1,052

 
1,206

 
2,258

 
1,305

 
3,563

 
1,383

 
4,946

 
1,259

 

 

 

 

 

 

 
20%
 
20%
Marketing, selling and administrative
 
1,068

 
1,238

 
2,306

 
1,144

 
3,450

 
1,461

 
4,911

 
1,074

 

 

 

 

 

 

 
1%
 
1%
Research and development
 
1,136

 
1,266

 
2,402

 
1,138

 
3,540

 
1,400

 
4,940

 
1,288

 

 

 

 

 

 

 
13%
 
13%
Other (income)/expense
 
(520
)
 
(454
)
 
(974
)
 
(224
)
 
(1,198
)
 
(87
)
 
(1,285
)
 
(647
)
 

 

 

 

 

 

 
24%
 
24%
Total Expenses
 
2,736

 
3,256

 
5,992

 
3,363

 
9,355

 
4,157

 
13,512

 
2,974

 

 

 

 

 

 

 
9%
 
9%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Earnings Before Income Taxes
 
$
1,655

 
$
1,615

 
$
3,270

 
$
1,559

 
$
4,829

 
$
1,086

 
$
5,915

 
$
1,955

 

 

 

 

 

 

 
18%
 
18%
Provision for Income Taxes
 
449

 
427

 
876

 
344

 
1,220

 
188

 
1,408

 
429

 

 

 

 

 

 

 
(4)%
 
(4)%
Net Earnings
 
$
1,206

 
$
1,188

 
$
2,394

 
$
1,215

 
$
3,609

 
$
898

 
$
4,507

 
$
1,526

 

 

 

 

 

 

 
27%
 
27%
Net Earnings/(Loss) Attributable to Noncontrolling Interest
 
11

 
22

 
33

 
13

 
46

 
4

 
50

 
(48
)
 

 

 

 

 

 

 
**
 
**
Net Earnings Attributable to BMS
 
$
1,195

 
$
1,166

 
$
2,361

 
$
1,202

 
$
3,563

 
$
894

 
$
4,457

 
$
1,574

 

 

 

 

 

 

 
32%
 
32%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted Earnings per Common Share*
 
$
0.71

 
$
0.69

 
$
1.41

 
$
0.72

 
$
2.12

 
$
0.53

 
$
2.65

 
$
0.94

 

 

 

 

 

 

 
32%
 
32%
Average Common Shares Outstanding - Diluted
 
1,680

 
1,679

 
1,679

 
1,679

 
1,679

 
1,680

 
1,680

 
1,671

 

 

 

 

 

 

 
(1)%
 
(1)%
Dividends declared per common share
 
$
0.38

 
$
0.38

 
$
0.76

 
$
0.38

 
$
1.14

 
$
0.39

 
$
1.53

 
$
0.39

 

 

 

 

 

 

 
3%
 
3%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2016
 
2017
 
 
 
 
% of Total Revenues
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
 
 
 
Gross Margin
 
76.0
%
 
75.2
%
 
75.6
%
 
73.5
%
 
74.9
%
 
73.6
%
 
74.5
%
 
74.5
%
 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Ratios
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
 
27.1
%
 
26.4
%
 
26.8
%
 
22.1
%
 
25.3
%
 
17.3
%
 
23.8
%
 
21.9
%
 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other (Income)/Expense
 
2016
 
2017
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Interest expense
 
$
43

 
$
42

 
$
85

 
$
42

 
$
127

 
$
40

 
$
167

 
$
45

 

 

 

 

 

 

 
5
 %
 
5
 %
Investment income
 
(24
)
 
(25
)
 
(49
)
 
(32
)
 
(81
)
 
(24
)
 
(105
)
 
(33
)
 

 

 

 

 

 

 
38
 %
 
38
 %
Provision for restructuring
 
4

 
18

 
22

 
19

 
41

 
68

 
109

 
164

 

 

 

 

 

 

 
**

 
**

Litigation and other settlements
 
43

 
6

 
49

 
(1
)
 
48

 
(1
)
 
47

 
(484
)
 

 

 

 

 

 

 
**

 
**

Equity in net income of affiliates
 
(26
)
 
(20
)
 
(46
)
 
(19
)
 
(65
)
 
(12
)
 
(77
)
 
(18
)
 

 

 

 

 

 

 
(31
)%
 
(31
)%
Divestiture gains
 
(270
)
 
(283
)
 
(553
)
 
(21
)
 
(574
)
 
(2
)
 
(576
)
 
(127
)
 

 

 

 

 

 

 
(53
)%
 
(53
)%
Royalties and licensing income
 
(254
)
 
(167
)
 
(421
)
 
(158
)
 
(579
)
 
(140
)
 
(719
)
 
(199
)
 

 

 

 

 

 

 
(22
)%
 
(22
)%
Transition and other service fees
 
(53
)
 
(74
)
 
(127
)
 
(57
)
 
(184
)
 
(54
)
 
(238
)
 
(7
)
 

 

 

 

 

 

 
(87
)%
 
(87
)%
Pension charges
 
22

 
25

 
47

 
19

 
66

 
25

 
91

 
33

 

 

 

 

 

 

 
50
 %
 
50
 %
Intangible asset impairments
 
15

 
—

 
15

 
—

 
15

 
—

 
15

 
—

 

 

 

 

 

 

 
(100
)%
 
(100
)%
Equity investment impairment
 
—

 
45

 
45

 
—

 
45

 
—

 
45

 
—

 

 

 

 

 

 

 
—

 
—

Other
 
(20
)
 
(21
)
 
(41
)
 
(16
)
 
(57
)
 
13

 
(44
)
 
(21
)
 

 

 

 

 

 

 
5
 %
 
5
 %
 
 
$
(520
)
 
$
(454
)
 
$
(974
)
 
$
(224
)
 
$
(1,198
)
 
$
(87
)
 
$
(1,285
)
 
$
(647
)
 

 

 

 

 

 

 
24
 %
 
24
 %
*
Quarterly amounts may not add to the year-to-date totals due to rounding of individual calculations.
**
In excess of +/- 100%


2

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT
FOR THE PERIOD ENDED MARCH 31, 2017
(Unaudited, dollars in millions)

QUARTER-TO-DATE
 
2017
 
2016
 
Growth $
 
Growth %
 
Favorable /
(Unfavorable)
FX Impact $ *
 
2017
Excluding FX
 
Favorable /
(Unfavorable)
FX Impact % *
 
Growth %
Excluding FX
Revenues
 
$
4,929

 
$
4,391

 
$
538

 
12%
 
$
(39
)
 
$
4,968

 
(1)%
 
13%
Gross profit
 
3,670

 
3,339

 
331

 
10%
 
N/A

 
N/A

 
N/A
 
N/A
Gross profit excluding specified items(a)
 
3,670

 
3,343

 
327

 
10%
 
N/A

 
N/A

 
N/A
 
N/A
          Gross profit excluding specified items as a % of revenues
 
74.5
%
 
76.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
1,288

 
1,136

 
152

 
13%
 
4

 
1,292

 
1%
 
14%
Research and development excluding specified items(a)
 
1,091

 
998

 
93

 
9%
 
4

 
1,095

 
1%
 
10%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Research and development excluding specified items as a % of revenues
 
22.1
%
 
22.7
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a)
Refer to the Specified Items schedule for further details.
 
 
 
 
 
 
 
 
 
 
 
 
 
*
Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales and expenses.

3

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
 
 
2016
 
2017
 
Growth $
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
 
Qtr vs. Qtr
 
YTD vs. YTD
Prioritized Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opdivo
 
$
704

 
$
840

 
$
1,544

 
$
920

 
$
2,464

 
$
1,310

 
$
3,774

 
$
1,127

 
 
 
 
 
 
 
 
 
 
 
 
 
$
423

 
$
423

 
60
 %
 
60
 %
Eliquis
 
734

 
777

 
1,511

 
884

 
2,395

 
948

 
3,343

 
1,101

 
 
 
 
 
 
 
 
 
 
 
 
 
367

 
367

 
50
 %
 
50
 %
Orencia(a)
 
475

 
593

 
1,068

 
572

 
1,640

 
625

 
2,265

 
535

 
 
 
 
 
 
 
 
 
 
 
 
 
60

 
60

 
13
 %
 
13
 %
Sprycel
 
407

 
451

 
858

 
472

 
1,330

 
494

 
1,824

 
463

 
 
 
 
 
 
 
 
 
 
 
 
 
56

 
56

 
14
 %
 
14
 %
Yervoy
 
263

 
241

 
504

 
285

 
789

 
264

 
1,053

 
330

 
 
 
 
 
 
 
 
 
 
 
 
 
67

 
67

 
25
 %
 
25
 %
Empliciti
 
28

 
34

 
62

 
41

 
103

 
47

 
150

 
53

 
 
 
 
 
 
 
 
 
 
 
 
 
25

 
25

 
89
 %
 
89
 %
Established Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hepatitis C Franchise(b)
 
427

 
546

 
973

 
379

 
1,352

 
226

 
1,578

 
162

 
 
 
 
 
 
 
 
 
 
 
 
 
(265
)
 
(265
)
 
(62
)%
 
(62
)%
Baraclude
 
291

 
299

 
590

 
306

 
896

 
296

 
1,192

 
282

 
 
 
 
 
 
 
 
 
 
 
 
 
(9
)
 
(9
)
 
(3
)%
 
(3
)%
Sustiva Franchise(c)
 
273

 
271

 
544

 
275

 
819

 
246

 
1,065

 
184

 
 
 
 
 
 
 
 
 
 
 
 
 
(89
)
 
(89
)
 
(33
)%
 
(33
)%
Reyataz Franchise
 
221

 
247

 
468

 
238

 
706

 
206

 
912

 
193

 
 
 
 
 
 
 
 
 
 
 
 
 
(28
)
 
(28
)
 
(13
)%
 
(13
)%
Other Brands
 
568

 
572

 
1,140

 
550

 
1,690

 
581

 
2,271

 
499

 
 
 
 
 
 
 
 
 
 
 
 
 
(69
)
 
(69
)
 
(12
)%
 
(12
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
$
4,391

 
$
4,871

 
$
9,262

 
$
4,922

 
$
14,184

 
$
5,243

 
$
19,427

 
$
4,929

 
 
 
 
 
 
 
 
 
 
 
 
 
$
538

 
$
538

 
12
 %
 
12
 %
(a)
Includes Orencia SubQ revenues of $244 million and $216 million for the three months ended March 31, 2017 and 2016, respectively.
(b)
Includes Daklinza (daclatasvir) revenues of $158 million and $420 million for the three months ended March 31, 2017 and 2016, respectively.
(c)
The Sustiva Franchise includes sales of Sustiva and revenue from sales of bulk efavirenz included in the combination therapy, Atripla. Includes alliance revenue of $158 million and $241 million for the three months ended March 31, 2017 and 2016, respectively.

4

BRISTOL-MYERS SQUIBB COMPANY
U.S. REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
 
 
2016
 
2017
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Prioritized Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opdivo
 
$
594

 
$
643

 
$
1,237

 
$
712

 
$
1,949

 
$
715

 
$
2,664

 
$
761

 
 
 
 
 
 
 
 
 
 
 
 
 
28
 %
 
28
 %
Eliquis
 
468

 
444

 
912

 
512

 
1,424

 
539

 
1,963

 
699

 
 
 
 
 
 
 
 
 
 
 
 
 
49
 %
 
49
 %
Orencia(a)
 
321

 
401

 
722

 
387

 
1,109

 
423

 
1,532

 
362

 
 
 
 
 
 
 
 
 
 
 
 
 
13
 %
 
13
 %
Sprycel
 
210

 
233

 
443

 
259

 
702

 
267

 
969

 
247

 
 
 
 
 
 
 
 
 
 
 
 
 
18
 %
 
18
 %
Yervoy
 
199

 
179

 
378

 
222

 
600

 
202

 
802

 
243

 
 
 
 
 
 
 
 
 
 
 
 
 
22
 %
 
22
 %
Empliciti
 
28

 
33

 
61

 
36

 
97

 
36

 
133

 
36

 
 
 
 
 
 
 
 
 
 
 
 
 
29
 %
 
29
 %
Established Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hepatitis C Franchise(b)
 
259

 
294

 
553

 
192

 
745

 
82

 
827

 
42

 
 
 
 
 
 
 
 
 
 
 
 
 
(84
)%
 
(84
)%
Baraclude
 
17

 
15

 
32

 
17

 
49

 
17

 
66

 
14

 
 
 
 
 
 
 
 
 
 
 
 
 
(18
)%
 
(18
)%
Sustiva Franchise(c)
 
228

 
227

 
455

 
234

 
689

 
212

 
901

 
153

 
 
 
 
 
 
 
 
 
 
 
 
 
(33
)%
 
(33
)%
Reyataz Franchise
 
120

 
122

 
242

 
125

 
367

 
117

 
484

 
88

 
 
 
 
 
 
 
 
 
 
 
 
 
(27
)%
 
(27
)%
Other Brands
 
93

 
97

 
190

 
94

 
284

 
95

 
379

 
93

 
 
 
 
 
 
 
 
 
 
 
 
 
—

 
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total(d)
 
$
2,537

 
$
2,688

 
$
5,225

 
$
2,790

 
$
8,015

 
$
2,705

 
$
10,720

 
$
2,738

 
 
 
 
 
 
 
 
 
 
 
 
 
8
 %
 
8
 %
(a)
Includes Orencia SubQ revenues of $146 million and $132 million for the three months ended March 31, 2017 and 2016, respectively.
(b)
Includes revenues of Daklinza (daclastasvir) only.
(c)
The Sustiva Franchise includes sales of Sustiva, as well as revenue from sales of bulk efavirenz included in the combination therapy, Atripla.
(d)
Includes United States and Puerto Rico.


5

BRISTOL-MYERS SQUIBB COMPANY
INTERNATIONAL REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)
 
 
2016
 
2017
 
% Change
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
Qtr vs. Qtr
 
YTD vs. YTD
Prioritized Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opdivo
 
$
110

 
$
197

 
$
307

 
$
208

 
$
515

 
$
595

 
$
1,110

 
$
366

 
 
 
 
 
 
 
 
 
 
 
 
 
**

 
**

Eliquis
 
266

 
333

 
599

 
372

 
971

 
409

 
1,380

 
402

 
 
 
 
 
 
 
 
 
 
 
 
 
51
 %
 
51
 %
Orencia
 
154

 
192

 
346

 
185

 
531

 
202

 
733

 
173

 
 
 
 
 
 
 
 
 
 
 
 
 
12
 %
 
12
 %
Sprycel
 
197

 
218

 
415

 
213

 
628

 
227

 
855

 
216

 
 
 
 
 
 
 
 
 
 
 
 
 
10
 %
 
10
 %
Yervoy
 
64

 
62

 
126

 
63

 
189

 
62

 
251

 
87

 
 
 
 
 
 
 
 
 
 
 
 
 
36
 %
 
36
 %
Empliciti
 
—

 
1

 
1

 
5

 
6

 
11

 
17

 
17

 
 
 
 
 
 
 
 
 
 
 
 
 
N/A

 
N/A

Established Brands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hepatitis C Franchise(a)
 
168

 
252

 
420

 
187

 
607

 
144

 
751

 
120

 
 
 
 
 
 
 
 
 
 
 
 
 
(29
)%
 
(29
)%
Baraclude
 
274

 
284

 
558

 
289

 
847

 
279

 
1,126

 
268

 
 
 
 
 
 
 
 
 
 
 
 
 
(2
)%
 
(2
)%
Sustiva Franchise(b)
 
45

 
44

 
89

 
41

 
130

 
34

 
164

 
31

 
 
 
 
 
 
 
 
 
 
 
 
 
(31
)%
 
(31
)%
Reyataz Franchise
 
101

 
125

 
226

 
113

 
339

 
89

 
428

 
105

 
 
 
 
 
 
 
 
 
 
 
 
 
4
 %
 
4
 %
Other Brands
 
475

 
475

 
950

 
456

 
1,406

 
486

 
1,892

 
406

 
 
 
 
 
 
 
 
 
 
 
 
 
(15
)%
 
(15
)%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total(c)
 
$
1,854

 
$
2,183

 
$
4,037

 
$
2,132

 
$
6,169

 
$
2,538

 
$
8,707

 
$
2,191

 
 
 
 
 
 
 
 
 
 
 
 
 
18
 %
 
18
 %

**
In excess of +/- 100%
(a)
Includes Daklinza (daclatasvir) revenues of $116 million and $161 million for the three months ended March 31, 2017 and 2016, respectively.
(b)
The Sustiva Franchise includes sales of Sustiva and revenue from sales of bulk efavirenz included in the combination therapy, Atripla.
(c)
When adjusted for foreign exchange impact, total revenues increased 20% for the first quarter.



6

BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
(Unaudited, dollars in millions)
 
 
2016
 
2017
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
Cost of products sold(a)
 
$
4

 
$
4

 
$
8

 
$
7

 
$
15

 
$
6

 
$
21

 
$
—

 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
License and asset acquisition charges
 
125

 
139

 
264

 
45

 
309

 
130

 
439

 
50

 

 

 

 

 

 

IPRD impairments
 
—

 
—

 
—

 
—

 
—

 
13

 
13

 
75

 

 

 

 

 

 

Accelerated depreciation and other
 
13

 
13

 
26

 
14

 
40

 
43

 
83

 
72

 

 

 

 

 

 

Research and development
 
138

 
152

 
290

 
59

 
349

 
186

 
535

 
197

 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Provision for restructuring
 
4

 
18

 
22

 
19

 
41

 
68

 
109

 
164

 

 

 

 

 

 

Divestiture gains
 
(269
)
 
(277
)
 
(546
)
 
(13
)
 
(559
)
 
—

 
(559
)
 
(100
)
 

 

 

 

 

 

Pension charges
 
22

 
25

 
47

 
19

 
66

 
25

 
91

 
33

 

 

 

 

 

 

Litigation and other settlements
 
43

 
—

 
43

 
(3
)
 
40

 
—

 
40

 
(481
)
 

 

 

 

 

 

Intangible asset impairments
 
15

 
—

 
15

 
—

 
15

 
—

 
15

 
—

 

 

 

 

 

 

Royalties and licensing income
 
—

 
—

 
—

 
—

 
—

 
(10
)
 
(10
)
 
—

 

 

 

 

 

 

Other (income)/expense
 
(185
)
 
(234
)
 
(419
)
 
22

 
(397
)
 
83

 
(314
)
 
(384
)
 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increase/(decrease) to pretax income
 
(43
)
 
(78
)
 
(121
)
 
88

 
(33
)
 
275

 
242

 
(187
)
 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Income taxes on specified items
 
83

 
76

 
159

 
(3
)
 
156

 
(105
)
 
51

 
72

 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increase/(decrease) to net earnings
 
40

 
(2
)
 
38

 
85

 
123

 
170

 
293

 
(115
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noncontrolling interest
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
(59
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increase/(decrease) to net earnings used for diluted Non-GAAP EPS calculation
 
$
40

 
$
(2
)
 
$
38

 
$
85

 
$
123

 
$
170

 
$
293

 
$
(174
)
 

 

 

 

 

 

(a)
Specified items in cost of products sold are accelerated depreciation, asset impairment and other shutdown costs.

7

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS
(Unaudited, dollars in millions)
 
 
2016
 
2017
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
Gross Profit
 
$
3,339

 
$
3,665

 
$
7,004

 
$
3,617

 
$
10,621

 
$
3,860

 
$
14,481

 
$
3,670

 

 

 

 

 

 

Specified items(a)
 
4

 
4

 
8

 
7

 
15

 
6

 
21

 
—

 

 

 

 

 

 

Gross profit excluding specified items
 
3,343

 
3,669

 
7,012

 
3,624

 
10,636

 
3,866

 
14,502

 
3,670

 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
1,136

 
1,266

 
2,402

 
1,138

 
3,540

 
1,400

 
4,940

 
1,288

 

 

 

 

 

 

Specified items(a)
 
(138
)
 
(152
)
 
(290
)
 
(59
)
 
(349
)
 
(186
)
 
(535
)
 
(197
)
 

 

 

 

 

 

Research and development excluding specified items
 
998

 
1,114

 
2,112

 
1,079

 
3,191

 
1,214

 
4,405

 
1,091

 

 

 

 

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other (income)/expense
 
(520
)
 
(454
)
 
(974
)
 
(224
)
 
(1,198
)
 
(87
)
 
(1,285
)
 
(647
)
 

 

 

 

 

 

Specified items(a)
 
185

 
234

 
419

 
(22
)
 
397

 
(83
)
 
314

 
384

 

 

 

 

 

 

Other (income)/expense excluding specified items
 
(335
)
 
(220
)
 
(555
)
 
(246
)
 
(801
)
 
(170
)
 
(971
)
 
(263
)
 

 

 

 

 

 


(a)
Refer to the Specified Items schedule for further details.


8

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF GAAP TO NON-GAAP EPS
(Unaudited, dollars in millions)
 
 
2016
 
2017
 
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
 
1st Qtr
 
2nd Qtr
 
6 Months
 
3rd Qtr
 
9 Months
 
4th Qtr
 
Year
Earnings before income taxes
 
$
1,655

 
$
1,615

 
$
3,270

 
$
1,559

 
$
4,829

 
$
1,086

 
$
5,915

 
$
1,955

 
 
 
 
 
 
 
 
 

 

Specified items(a)
 
(43
)
 
(78
)
 
(121
)
 
88

 
(33
)
 
275

 
242

 
(187
)
 
 
 
 
 
 
 
 
 

 

Earnings before income taxes excluding specified items
 
1,612

 
1,537

 
3,149

 
1,647

 
4,796

 
1,361

 
6,157

 
1,768

 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Provision for income taxes
 
449

 
427

 
876

 
344

 
1,220

 
188

 
1,408

 
429

 
 
 
 
 
 
 
 
 

 

Tax on specified items(a)
 
83

 
76

 
159

 
(3
)
 
156

 
(105
)
 
51

 
72

 
 
 
 
 
 
 
 
 

 

Provision for income taxes excluding tax on specified items
 
366

 
351

 
717

 
347

 
1,064

 
293

 
1,357

 
357

 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Earnings/(Loss) Attributable to Noncontrolling Interest
 
11

 
22

 
33

 
13

 
46

 
4

 
50

 
(48
)
 
 
 
 
 
 
 
 
 
 
 
 
Specified items(a)
 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
(59
)
 
 
 
 
 
 
 
 
 
 
 
 
Net Earnings Attributable to Noncontrolling Interest excluding specified items
 
11

 
22

 
33

 
13

 
46

 
4

 
50

 
11

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net earnings attributable to BMS used for Diluted EPS Calculation - GAAP
 
1,195

 
1,166

 
2,361

 
1,202

 
3,563

 
894

 
4,457

 
1,574

 
 
 
 
 
 
 
 
 

 

Specified items(a)
 
40

 
(2
)
 
38

 
85

 
123

 
170

 
293

 
(174
)
 
 
 
 
 
 
 
 
 

 

Net earnings attributable to BMS used for Diluted EPS Calculation excluding specified items - Non-GAAP
 
1,235

 
1,164

 
2,399

 
1,287

 
3,686

 
1,064

 
4,750

 
1,400

 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average Common shares Outstanding - Diluted- GAAP
 
1,680

 
1,679

 
1,679

 
1,679

 
1,679

 
1,680

 
1,680

 
1,671

 
 
 
 
 
 
 
 
 

 

Weighted-average Common shares Outstanding - Diluted- Non-GAAP
 
1,680

 
1,679

 
1,679

 
1,679

 
1,679

 
1,680

 
1,680

 
1,671

 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted Earnings Per Share - GAAP
 
$
0.71

 
$
0.69

 
$
1.41

 
$
0.72

 
$
2.12

 
$
0.53

 
$
2.65

 
$
0.94

 
 
 
 
 
 
 
 
 

 

Diluted Earnings Per Share attributable to specified items
 
0.03

 
—

 
0.02

 
0.05

 
0.08

 
0.10

 
0.18

 
(0.10
)
 
 
 
 
 
 
 
 
 

 

Diluted Earnings Per Share - Non-GAAP
 
$
0.74

 
$
0.69

 
$
1.43

 
$
0.77

 
$
2.20

 
$
0.63

 
$
2.83

 
$
0.84

 
 
 
 
 
 
 
 
 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective Tax Rate
 
27.1
 %
 
26.4
 %
 
26.8
 %
 
22.1
 %
 
25.3
 %
 
17.3
%
 
23.8
 %
 
21.9
 %
 
 
 
 
 
 
 
 
 

 

Specified items (a)
 
(4.4
)%
 
(3.6
)%
 
(4.0
)%
 
(1.0
)%
 
(3.1
)%
 
4.2
%
 
(1.8
)%
 
(1.7
)%
 
 
 
 
 
 
 
 
 

 

Effective Tax Rate excluding specified items
 
22.7
 %
 
22.8
 %
 
22.8
 %
 
21.1
 %
 
22.2
 %
 
21.5
%
 
22.0
 %
 
20.2
 %
 
 
 
 
 
 
 
 
 

 

(a)
Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

9

BRISTOL-MYERS SQUIBB COMPANY
SELECTED BALANCE SHEET INFORMATION
(Unaudited, dollars in millions)
 
 
 
March 31,
2016
 
June 30,
2016
 
September 30,
2016
 
December 31,
2016
 
March 31,
2017
 
June 30,
2017
 
September 30,
2017
 
December 31,
2017
Cash and cash equivalents
 
$
2,644

 
$
2,934

 
$
3,432

 
$
4,237

 
$
3,910

 

 

 

Marketable securities - current
 
1,663

 
1,717

 
2,128

 
2,113

 
2,199

 

 

 

Marketable securities - non-current
 
3,689

 
3,281

 
3,035

 
2,719

 
2,685

 

 

 

     Cash, cash equivalents and marketable securities
 
7,996

 
7,932

 
8,595

 
9,069

 
8,794

 

 

 

 
 
 
 
 
 
 
 
 
 


 
 
 
 
 
 
Short-term debt obligations
 
(106
)
 
(155
)
 
(990
)
 
(992
)
 
(1,197
)
 

 

 

Long-term debt
 
(6,593
)
 
(6,581
)
 
(5,836
)
 
(5,716
)
 
(7,237
)
 

 

 

     Net cash position
 
$
1,297

 
$
1,196

 
$
1,769

 
$
2,361

 
$
360

 

 

 



10

BRISTOL-MYERS SQUIBB COMPANY
2017 FULL YEAR PROJECTED DILUTED EPS FROM OPERATIONS
EXCLUDING PROJECTED SPECIFIED ITEMS
 
 
Full Year 2017
 
 
 
 
 
 
 
 
Pre-tax
 
Tax
 
After-tax
 
Projected Diluted Earnings Attributable to Shareholders per Common Share - GAAP
 
 
 
 
$2.72 to $2.87

 
 
 
 
 
 
 
 
 
 
Projected Specified Items:
 
 
 
 
 
 
Restructuring, accelerated depreciation and other shutdown costs (1)
0.35

 
0.12

 
0.23

 
Divestiture gains and licensing income
(0.36
)
 
(0.13
)
 
(0.23
)
 
Research and development license and asset acquisition charges
0.31

 
0.05

 
0.26

 
Pension charges
0.11

 
0.04

 
0.07

 
Litigation and other settlements
(0.29
)
 
(0.10
)
 
(0.19
)
 
Other
0.01

 
0.02

 
(0.01
)
 
Total
0.13

 
—

 
0.13

 
 
 
 
 
 
 
 
 
 
Projected Diluted Earnings Attributable to Shareholders per Common Share - non-GAAP
 
 
 
 
$2.85 to $3.00

 
 
 
 
 
 
 
 
 
 
(1) Includes items recognized in Research and development and Other (income)/expense.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following table summarizes the company's 2017 financial guidance:
 
Line item
 
GAAP
 
Non-GAAP
 
Gross margin as a percent of revenue
 
Approximately 72%-73%
 
Approximately 72%-73%
 
Marketing, selling and administrative expense
 
Decrease in mid to high-single digits compared to 2016
 
Decrease in mid to high-single digits compared to 2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development expense
 
Increase in the high-teens digits compared to 2016
 
Increase in the low double digits compared to 2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
 
Approximately 22%
 
Approximately 21%
The GAAP financial results for the full year 2017 will include specified items, including gains on divestitures, upfront payments from out licensed assets, charges associated with restructuring, downsizing and streamlining worldwide operations, license and asset acquisition charges, litigation and other settlements, licensed asset impairments and pension charges.  The GAAP financial results for 2017 could also include other specified items that have not yet been identified and quantified, including any additional gains or losses from divestitures, license and asset acquisition charges, licensed asset impairments, litigation and other settlements and significant tax events, among other items. For a fuller discussion of certain litigation and other matters that could impact full year GAAP results, as well as the use of non-GAAP financial information, see Bristol-Myers Squibb Reports First Quarter 2017 Financial Results, April 27, 2017 including “2017 Financial Guidance” and “Use of non-GAAP Financial Information” therein. 


11
 GRAPHIC 4 bmslogoq12017.jpg GRAPHIC begin 644 bmslogoq12017.jpg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end